https://orcid.org/0000-0001-6980-0709
References
- Talamonti M, Galluzzo M, Chiricozzi A, et al. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. J Drugs Dermatol. 2012;11(8):1000–1002.
- Adamczyk M, Michalska-Jakubus M, Krasowska D. A 12-year-old girl with severe plaque psoriasis and Down syndrome treated successfully with etanercept. Acta Dermatovenerol Croat. 2017;25(2):155–158.
- Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet. 2009;126(1):195–214. doi:10.1007/s00439-009-0696-8
- Madan V, Williams J, Lear JT. Dermatological manifestations of Down’s syndrome. Clin Exp Dermatol. 2006;31(5):623–629. doi:10.1111/j.1365-2230.2006.02164.x
- Marmon S, De Souza A, Strober BE. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J. 2012;18(6):13. doi:10.5070/D305M5F4BX
- Sismour B, D’Acunto K. Down syndrome, severe psoriasis, and increased risk for cardiovascular events. J Am Acad Physician Assist. 2019;32(12):31–33. doi:10.1097/01.JAA.0000604860.71819.c1
- Mohd Affandi A, Khan I, Ngah Saaya N. Epidemiology and clinical features of adult patients with psoriasis in Malaysia: 10-year review from the Malaysian Psoriasis Registry (2007–2016). Dermatol Res Pract. 2018;2018:1–8. doi:10.1155/2018/4371471
- Alcaide AJ, Barrera MV, Habicheyn S, López N, Mendiola MV, Herrera E. Safety of etanercept therapy in a patient with psoriasis, Down’s syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol. 2008;22(12):1514–1516. doi:10.1111/j.1468-3083.2008.02693.x
- Wu JJ, Valdecantos WC. Adalimumab in chronic plaque psoriasis: a Clinical Guide. J Drugs Dermatol. 2017;16(8):779–790.
- Burness CB, McKeage K. Adalimumab: a Review in Chronic Plaque Psoriasis. Drugs. 2015;75(18):2119–2130. doi:10.1007/s40265-015-0503-x
- Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31(11):1853–1859. doi:10.1111/jdv.14146
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. doi:10.1016/j.jaad.2018.06.056